Seres Therapeutics Inc expected to post a loss of $2.49 a share - Earnings Preview

Seres Therapeutics

04/08/2025 14:43

Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

​LSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of $2.49 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Seres Therapeutics Inc is $14.00, about 0.1% above its last closing price of $13.99

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.25
-0.54
-2.96
Missed
-448.1
Dec. 31 2025
-3.75
-3.94
-2.00
Beat
49.2
Sep. 30 2024
-4.88
-4.91
-7.60
Missed
-54.8​
Jun. 30 2024
-5.46
-5.48
-4.40
Beat
19.7
​​Mar. 31 2024
-6.95
-6.82
-5.40
Beat
20.8
Dec. 31 2023
-7.95
-9.94
-6.40
Beat
35.6​
Sep. 30 2023
-9.87
-10.03
-7.40
Beat
26.2
Jun. 30 2023
10.58
10.68
7.20
Missed
-32.6

This summary was machine generated August 4 at 13:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)